Validation of the French Version of the Perinatal Assessment of Paternal Affectivity (PAPA)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Clermont-Ferrand

About this trial

The transition to parenthood is a critical period for both the woman and her partner, and this can affect the mental health of the parents. Like mothers, fathers are at risk of stress, anxiety, depression and post-traumatic stress disorder during the perinatal period.

Existing screening or diagnostic tools have been developed on the basis of traditional depressive symptoms expressed by women. However, the manifestations of perinatal mental disorders appear to be different in men. It is therefore essential to develop tools that are sensitive and specific to both gender and the perinatal period in order to increase the sensitivity and specificity of screening for fathers.

In France, to the best of the knowledge of the investigators, there is no validated tool in French to assess paternal psychological disorders, either prenatally or postnatally. Baldoni et al. had validated a brief self-report questionnaire, the " Perinatal Assessment of Paternal Affectivity " (PAPA), to screen for perinatal signs and symptoms of paternal affective disorder, using a gender-sensitive approach.

The aim of this study is to cross-cultural adapt the PAPA in French and to evaluate its psychometric properties.

This validation of the French-PAPA would provide a simple tool, easy to use in everyday practice, to detect any signs or symptoms of paternal psychopathological distress in the pre- and postnatal period.

Eligibility criteria

Qualifiers

Woman and its male partner aged 18 years old and older

Couple understanding, speaking and reading French

Couple giving their informed consent to participate voluntarily

Disqualifiers

Woman without male partner

Woman admitted to intensive care after giving birth

Couple whose newborn died peripartum

Couple who have had a medical abortion or fetal death in utero for the current pregnancy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed